Abstract: Since the end of December 2019, novel coronavirus pneumonia(COVID-19) has been prevalent in China and many foreign countries, mainly through respiratory droplets and close contact transmission. There are also possible transmission routes such as aerosols and feces. Its incubation period is long, and all people are generally susceptible to it. As one of the treatment methods for intraperitoneal tumors, hyperthermic intraperitoneal chemotherapy (HIPEC) is widely used in the field of gynecological malignant tumors. During the epidemic period of COVID-19, patients with gynecologic malignant tumors were more susceptible to 2019 novel coronavirus (2019-nCoV) than the general population due to low autoimmunity and other reasons, resulting in a significantly increased risk of HIPEC. Therefore, before performing HIPEC, patients with gynecological malignant tumors must strictly perform COVID-19-related screening to exclude 2019-nCoV infections. We should carefully control indications and contraindications, establish a multidisciplinary joint consultation system, develop personalized diagnosis and treatment plans according to the patient′s condition, and take the balance between epidemic prevention and control and cancer treatment into account. During the treatment of HIPEC, attention should be paid to strengthening doctor-patient protection and monitoring of various indicators. Strict follow-up and health guidance after HIPEC treatment are necessary. In order to better guide clinical diagnosis and treatment, this article tend to described how to perform HIPEC safely and effectively for patients with gynecological malignant tumors during the COVID-19 epidemic period.

Key words: Novel coronavirus pneumonia, Gynecological malignant tumor;, Genital neoplasms, female;, Hyperthermic intraperitoneal chemotherapy, Infusions, parenteral;, Chemotherapy, cancer, regional perfusion, Neoadjuvant therapy